10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2021 | |||
Consolidated Statements of Operations | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 23, 2022) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Revenue (Note 2) | $ 28,318,400 | 24,539,800 | 22,319,500 |
| Costs, expenses, and other: | |||
| Cost of sales | 7,312,800 | 5,483,300 | 4,721,200 |
| Research and development | 7,025,900 | 6,085,700 | 5,595,000 |
| Marketing, selling, and administrative | 6,431,600 | 6,121,200 | 6,213,800 |
| Acquired in-process research and development (Note 3) | 874,900 | 660,400 | 239,600 |
| Asset impairment, restructuring, and other special charges (Note 5) | 316,100 | 131,200 | 575,600 |
| Othernet, (income) expense (Note 18) | 201,600 | (1,171,900) | (291,600) |
| Costs, expenses, and other | 22,162,900 | 17,309,900 | 17,053,600 |
| Income before income taxes | 6,155,500 | 7,229,900 | 5,265,900 |
| Income taxes (Note 14) | 573,800 | 1,036,200 | 628,000 |
| Net income from continuing operations | 5,581,700 | 6,193,700 | 4,637,900 |
| Net income from discontinued operations (Note 19) | 0 | 0 | 3,680,500 |
| Net income | 5,581,700 | 6,193,700 | 8,318,400 |
| Earnings per share: | |||
| Earnings from continuing operations - basic (in usd per share) | 6.15 | 6.82 | 4.98 |
| Earnings from discontinued operations - basic (in usd per share) | 0.00 | 0.00 | 3.95 |
| Earnings per share - basic (in usd per share) | 6.15 | 6.82 | 8.93 |
| Earnings from continuing operations - diluted (in usd per share) | 6.12 | 6.79 | 4.96 |
| Earnings from discontinued operations - diluted (in usd per share) | 0.00 | 0.00 | 3.93 |
| Earnings per share - diluted (in usd per share) | 6.12 | 6.79 | 8.89 |
| Shares used in calculation of earnings per share: | |||
| Basic (in shares) | 906,963 | 907,634 | 931,059 |
| Diluted (in shares) | 911,681 | 912,505 | 935,684 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2021 | |||
Consolidated Statements of Comprehensive Income (Loss) | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 23, 2022) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Net income | $ 5,581,700 | 6,193,700 | 8,318,400 |
| Other comprehensive income (loss) from continuing operations: | |||
| Change in foreign currency translation gains (losses) | 13,500 | 122,100 | (89,900) |
| Change in net unrealized gains (losses) on securities | (15,900) | 14,200 | 34,400 |
| Change in defined benefit pension and retiree health benefit plans (Note 15) | 2,699,400 | (157,100) | (970,000) |
| Change in effective portion of cash flow hedges | 151,600 | (152,900) | 34,300 |
| Other comprehensive income (loss) from continuing operations before income taxes | 2,848,600 | (173,700) | (991,200) |
| Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations | (695,300) | 200,900 | 151,000 |
| Net other comprehensive income (loss) | 2,153,300 | 27,200 | (783,400) |
| Comprehensive income | 7,735,000 | 6,220,900 | 7,535,000 |
| Operating Activities | |||
| Continuing Operations | |||
| Net other comprehensive income (loss) | 2,153,300 | 27,200 | (840,200) |
| Discontinued Operations | |||
| Net other comprehensive income (loss) | 0 | 0 | 56,800 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2021 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 23, 2022) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] | |||
| Cash Flows from Operating Activities | |||
| Net income | $ 5,581,700 | 6,193,700 | 8,318,400 |
| Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: | |||
| Gain related to disposition of Elanco (Note 19) | 0 | 0 | (3,680,500) |
| Gain on sale of antibiotic business in China (Note 3) | 0 | 0 | (309,800) |
| Depreciation and amortization | 1,547,600 | 1,323,900 | 1,232,600 |
| Debt extinguishment loss (Note 11) | 405,200 | 0 | 252,500 |
| Change in deferred income taxes | (802,300) | (134,500) | 62,400 |
| Stock-based compensation expense | 342,800 | 308,100 | 312,400 |
| Net investment gains | (178,000) | (1,438,500) | (403,100) |
| Acquired in-process research and development (Note 3) | 874,900 | 660,400 | 239,600 |
| Other non-cash operating activities, net | 511,400 | 333,900 | 499,300 |
| Other changes in operating assets and liabilities, net of acquisitions and divestitures: | |||
| Receivables(increase) decrease | (1,278,300) | (1,350,200) | (127,200) |
| Inventories(increase) decrease | (235,900) | (533,400) | (258,700) |
| Other assets(increase) decrease | 1,515,400 | (457,100) | (602,300) |
| Income taxes payableincrease (decrease) | (359,700) | 322,000 | (221,300) |
| Accounts payable and other liabilitiesincrease (decrease) | (664,100) | 1,271,300 | (477,700) |
| Net Cash Provided by Operating Activities | 7,260,700 | 6,499,600 | 4,836,600 |
| Cash Flows from Investing Activities | |||
| Purchases of property and equipment | (1,309,800) | (1,387,900) | (1,033,900) |
| Proceeds from sales and maturities of short-term investments | 47,400 | 129,700 | 136,600 |
| Purchases of short-term investments | (83,500) | (11,400) | (42,700) |
| Proceeds from sales of noncurrent investments | 800,000 | 757,100 | 609,800 |
| Purchases of noncurrent investments | (929,900) | (358,700) | (247,500) |
| Purchases of in-process research and development | (563,400) | (641,200) | (319,600) |
| Cash paid for acquisitions, net of cash acquired (Note 3) | (747,400) | (849,300) | (6,917,700) |
| Cash distributed to Elanco upon disposition | 0 | 0 | (374,000) |
| Cash received for sale of antibiotic business in China | 0 | 0 | 354,800 |
| Other investing activities, net | 24,300 | 102,800 | (248,700) |
| Net Cash Used for Investing Activities | (2,762,300) | (2,258,900) | (8,082,900) |
| Cash Flows from Financing Activities | |||
| Dividends paid | (3,086,800) | (2,687,100) | (2,409,800) |
| Net change in short-term borrowings | (4,000) | (1,494,200) | 995,400 |
| Proceeds from issuance of long-term debt | 2,410,800 | 2,062,300 | 6,556,400 |
| Repayments of long-term debt | (1,905,400) | (276,500) | (2,866,400) |
| Purchases of common stock | (1,250,000) | (500,000) | (4,400,000) |
| Other financing activities, net | (295,900) | (241,600) | (200,100) |
| Net Cash Used for Financing Activities | (4,131,300) | (3,137,100) | (2,324,500) |
| Effect of exchange rate changes on cash and cash equivalents | (205,700) | 216,000 | (89,900) |
| Net increase (decrease) in cash and cash equivalents | 161,400 | 1,319,600 | (5,660,700) |
| Cash and cash equivalents at beginning of year (2019 includes $677.5 of discontinued operations) | 3,657,100 | 2,337,500 | |
| Cash and Cash Equivalents at End of Year | 3,818,500 | 3,657,100 | 2,337,500 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ELI LILLY & CO | ||
Ticker: LLY Fiscal Year: 2021 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2021 10-K (Filed: Feb 23, 2022) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2021 | Dec 31, 2020 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents (Note 7) | $ 3,818,500 | 3,657,100 |
| Short-term investments (Note 7) | 90,100 | 24,200 |
| Accounts receivable, net of allowances of $22.5 (2021) and $25.9 (2020) | 6,672,800 | 5,875,300 |
| Other receivables | 1,454,400 | 1,053,700 |
| Inventories (Note 6) | 3,886,000 | 3,980,300 |
| Prepaid expenses and other | 2,530,600 | 2,871,500 |
| Total current assets | 18,452,400 | 17,462,100 |
| Investments (Note 7) | 3,212,600 | 2,966,800 |
| Goodwill (Note 8) | 3,892,000 | 3,766,500 |
| Other intangibles, net (Note 8) | 7,691,900 | 7,450,000 |
| Deferred tax assets (Note 14) | 2,489,300 | 2,830,400 |
| Property and equipment, net (Note 9) | 8,985,100 | 8,681,900 |
| Other noncurrent assets | 4,082,700 | 3,475,400 |
| Total assets | 48,806,000 | 46,633,100 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Short-term borrowings and current maturities of long-term debt (Note 11) | 1,538,300 | 8,700 |
| Accounts payable | 1,670,600 | 1,606,700 |
| Employee compensation | 958,100 | 997,200 |
| Sales rebates and discounts | 6,845,800 | 5,853,000 |
| Dividends payable | 885,500 | 770,600 |
| Income taxes payable (Note 14) | 126,900 | 495,100 |
| Other current liabilities | 3,027,500 | 2,750,300 |
| Total current liabilities | 15,052,700 | 12,481,600 |
| Other Liabilities | ||
| Long-term debt (Note 11) | 15,346,400 | 16,586,600 |
| Accrued retirement benefits (Note 15) | 1,954,100 | 4,094,500 |
| Long-term income taxes payable (Note 14) | 3,920,000 | 3,837,800 |
| Deferred tax liabilities (Note 14) | 1,733,700 | 2,099,900 |
| Other noncurrent liabilities | 1,644,300 | 1,707,500 |
| Total other liabilities | 24,598,500 | 28,326,300 |
| Commitments and Contingencies (Note 16) | ||
| Eli Lilly and Company Shareholders' Equity (Notes 12 and 13) | ||
| Common stockno par value Authorized shares: 3,200,000 Issued shares: 954,116 (2021) and 957,077 (2020) | 596,300 | 598,200 |
| Additional paid-in capital | 6,833,400 | 6,778,500 |
| Retained earnings | 8,958,500 | 7,830,200 |
| Employee benefit trust | (3,013,200) | (3,013,200) |
| Accumulated other comprehensive loss (Note 17) | (4,343,100) | (6,496,400) |
| Cost of common stock in treasury | (52,700) | (55,700) |
| Total Eli Lilly and Company shareholders' equity | 8,979,200 | 5,641,600 |
| Noncontrolling interests | 175,600 | 183,600 |
| Total equity | 9,154,800 | 5,825,200 |
| Total liabilities and equity | 48,806,000 | 46,633,100 |
| External Links | |
| ELI LILLY & CO (LLY) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |